Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses

19Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The therapeutic potential of oncolytic adenoviruses is limited by the rate of adenovirus release. Based on the observation that several viruses induce cell death and progeny release by disrupting intracellular calcium homeostasis, we hypothesized that the alteration in intracellular calcium concentration induced by verapamil could improve the rate of virus release and spread, eventually enhancing the antitumoral activity of oncolytic adenoviruses. Our results indicate that verapamil substantially enhanced the release of adenovirus from a variety of cell types resulting in an improved cell-to-cell spread and cytotoxicity. Furthermore, the combination of the systemic administration of an oncolytic adenovirus (ICOVIR-5) with verapamil in vivo greatly improved its antitumoral activity in two different tumor xenograft models without affecting the selectivity of this virus. Overall, our findings indicate that verapamil provides a new, safe, and versatile way to improve the antitumoral potency of oncolytic adenoviruses in the clinical setting. © The American Society of Gene & Cell Therapy.

Cite

CITATION STYLE

APA

Gros, A., Puig, C., Guedan, S., Rojas, J. J., Alemany, R., & Cascallo, M. (2010). Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. Molecular Therapy, 18(5), 903–911. https://doi.org/10.1038/mt.2010.22

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free